Cord Blood News 9.16 April 27, 2017 | |
| |
TOP STORYScientists hypothesized that a nitric oxide (NO)-releasing polymer can boost the proangiogenic compositions of exosomes and enhance their proangiogenic capacity. Their results demonstrated that exosomes, released from human placenta-derived mesenchymal stem cells by NO stimulation, augment the angiogenic effects of human umbilical vein endothelial cells in vitro. [Biomaterials] Abstract | |
| |
PUBLICATIONS(Ranked by impact factor of the journal)The authors systematically compared the morphologic characteristics, immunophenotypes and the adipogenic differentiation of mesenchymal stem cells (MSCs) derived from umbilical cord (UC), adipose tissue (Ad) and bone marrow (BM). They found that the three tissues-derived MSCs displayed decreased adipogenic capacity in the order: Ad-MSC > BM-MSC > UC-MSC, and no morphologic and immunophenotypic differences were observed. [Sci Rep] Full Article Cord Blood Hematopoietic Cells from Preterm Infants Display Altered DNA Methylation Patterns Researchers evaluated the epigenetic impact of preterm birth in isolated hematopoietic cell populations, reducing the concern of cell composition differences. DNA methylation (DNAm) differences in hematopoietic cells between term and <31 weeks were consistent with the hematopoietic origin of these cells during ontogeny, reflecting an important role of DNAm in their regulation. [Clin Epigenetics] Full Article The authors performed a retrospective analysis to identify risk factors associated with the five-year cumulative incidence of relapse after unrelated cord blood transplantation. Receiving a fully HLA matched graft was a strong risk factor for increased relapse in multivariate analysis. An exploratory analysis of all 640 patients supported the important association between the presence of acute graft-versus-host disease and less relapse, but also demonstrated an increased risk of NRM. [Biol Blood Marrow Transplant] Abstract Scientists investigated how hypoxia, dimethyloxaloylglycine (DMOG) and stemregenin 1 may affect the expansion of hematopoietic stem and progenitor cells with the aim of identifying optimal conditions for expansion in culture. It was found that DMOG decreased proliferation but was effective in preserving the number of cells in the primitive hematopoietic sub-populations in vitro. [Stem Cell Res] Full Article Only a few studies have focused on the functional heterogeneity of umbilical cord blood (CB)-endothelial colony forming cells (ECFCs) from different individuals. The detailed clonogenic profile of CB-ECFCs and peripheral adult blood-ECFCs was obtained and revealed a high inter individual heterogeneity and the absence of correlation with age. [Stem Cell Res] Full Article Investigators describe the development of a Current Good Manufacturing Practice-compliant process to isolate, expand and bank placenta-derived mesenchymal stromal cells (PMSCs) for use as stem cell therapy. They characterized the viability, proliferation and neuroprotective secretory profile of PMSCs seeded on clinical-grade porcine small intestine submucosa extracellular matrix. [Cytotherapy] Abstract To produce a clinically relevant and effective immunotherapy, scientists hypothesized that it is essential that the natural killer (NK) cells are able to proliferate and persist in vivo while maintaining an optimal activation status and killing capacity. They found that the differentiated NK cells could respond to interleukin-2 and proliferate in vitro. Telomere length was significantly increased, whereas CD57 expression was significantly reduced compared with peripheral blood NK cells. [Cytotherapy] Abstract Researchers designed a new biomimetic spongy scaffold from decellularized Wharton’s jelly-derived extracellular matrix and used it as a skin substitute. Histological analysis and biochemical assays showed that bio-active molecules preserved in the fabricated scaffolds and that the scaffolds have highly interconnected porous structure. [Mater Sci Eng C Mater Biol Appl] Abstract Lymphocytes were harvested from murine neonates at different ages, human late preterm and term cord blood, and adult peripheral blood. Human samples were activated over a five-day period to simulate acute inflammation. CD31-expressing neonatal murine CD4+ and CD8a+ T cells increased over the first week of life. Upon in vitro stimulation, human infants’ CD4+ and CD8a+ T cells shed CD31 faster in comparison with adults. [Pediatr Res] Abstract | |
| |
REVIEWSA Review of Infectious Complications after Haploidentical Hematopoietic Stem Cell Transplantations The authors focus on the infectious complications after haploidentical hematopoietic stem cell transplantation (HSCT). A shift towards T cell repletes haplo-HSCT with post-transplant cyclophosphamide for graft vs host disease has emerged in recent years, in which the incidence of viral and fungal infections is detected to be lower. [Infection] Abstract Visit our reviews page to see a complete list of reviews in the cord blood research field. | |
| |
INDUSTRY NEWSThe U.S. Attorney’s Office announced that Partners HealthCare System and one of its hospitals, Brigham and Women’s Hospital (BWH), have agreed to pay $10 million to resolve allegations that a BWH stem cell research laboratory run by Dr. Piero Anversa fraudulently obtained grant funding from the National Institutes of Health. [U.S. Department of Justice] Press Release Burst Biologics Initiates Clinical Study in Foot and Ankle Surgery Patients Burst Biologics announced their latest IRB approval to begin a multicenter prospective clinical study in Foot and Ankle Surgery patients. Burst Biologics latest product innovation, BioBurst® Fluid, is a cellular tissue product derived from umbilical cord blood. [Burst Biologics (PR Newswire Association LLC.)] Press Release | |
| |
POLICY NEWSBioRxiv Preprint Server Gets Cash Boost from Chan Zuckerberg Initiative BioRxiv, the hub for preliminary versions of biology research papers, has announced that it will begin receiving “significant” financial support from the Chan Zuckerberg Initiative, a philanthropic effort started by Facebook co-founder Mark Zuckerberg and his physician wife Priscilla Chan. [Nature News] Editorial California’s $3-Billion Bet on Stem Cells Faces Final Test When California voters approved US$3 billion in funding for stem-cell research in 2004, biologists flocked to the state, and citizens dreamed of cures for Parkinson’s disease and spinal-cord injuries. Now, the pot of money — one of the biggest state investments in science — is running dry before treatments have emerged, raising questions about whether Californians will pour billions more into stem-cell research. [Nature News] Editorial NSF’s Uphill Road to Making Prestigious Early Career Award More Diverse Only five women have won the National Science Foundation’s (NSF) annual Alan T. Waterman Award in its 41-year history, and no woman of color has ever been selected. The 2017 winners announced this month mark the 13th year in a row that the $1 million research prize has gone to a man (two, actually, including the second black scientist ever chosen). [ScienceInsider] Editorial
| |
EVENTSNEW American Association of Blood Banks (AABB) Visit our events page to see a complete list of events in the community.
| |
JOB OPPORTUNITIESNEW Research Associate – Blood Stem Cells (University of Cambridge) Postdoctoral Position – Leukemia Research (VIB-KU Leuven Center) Postdoctoral Position – Regulation of HSCs by Niche Cells (Technical University Dresden) Full Professor – Stem Cell Transplantation (Dana-Farber/Boston Children’s Hospital) Postdoctoral Fellow – Cancer Research (German Cancer Research Center) Postdoctoral Fellow – Stem Cell Research (Helmholtz Association) Postdoctoral Fellow – Leukemia Research (Children’s Hospital Los Angeles) Research Group Leader – Leukemia Research (University Hospital Basel) Full Member Faculty – Hematopoietic Cell Transplant Program (Fred Hutchinson Cancer Research Center) Assistant Member Faculty – Platinum/Immunotherapy (Fred Hutchinson Cancer Research Center) Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.
| |
Have we missed an important article or publication in Cord Blood News? Click here to submit! Comments or suggestions? Submit your feedback here. | |
|